Blurbs

Analysts Are Bullish on These Healthcare Stocks: Tricida (TCDA), Athira Pharma (ATHA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tricida (TCDAResearch Report) and Athira Pharma (ATHAResearch Report) with bullish sentiments.

Tricida (TCDA)

Needham analyst Serge Belanger maintained a Buy rating on Tricida today and set a price target of $18.00. The company’s shares closed last Monday at $10.80.

According to TipRanks.com, Belanger is a 4-star analyst with an average return of 8.8% and a 48.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tricida with a $15.33 average price target, a 41.7% upside from current levels. In a report released today, Goldman Sachs also maintained a Buy rating on the stock with a $20.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Athira Pharma (ATHA)

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Athira Pharma, with a price target of $6.00. The company’s shares closed last Monday at $3.81, close to its 52-week low of $2.53.

According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of 1.0% and a 51.5% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Harmony Biosciences Holdings, and Intra-Cellular Therapies.

Athira Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $13.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TCDA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed